Difference between revisions of "He SZ, et al. Leuk. Lymphoma (2015) cited as Ref 556 in DOI: 10.1038/s41392-020-0110-5 (Q9819)"
Jump to navigation
Jump to search
(Created a new Item: #quickstatements; #temporary_batch_1589975872009) |
(Created claim: Page(s) (P105): 1406-1415, #quickstatements; #temporary_batch_1590074839150) |
||||||||||||||
| (8 intermediate revisions by the same user not shown) | |||||||||||||||
| Property / First Author string | |||||||||||||||
| + | He SZ | ||||||||||||||
| Property / First Author string: He SZ / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / DOI Identifier | |||||||||||||||
| + | |||||||||||||||
| Property / DOI Identifier: 10.3109/10428194.2014.956316 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / PubMed ID | |||||||||||||||
| + | |||||||||||||||
| Property / PubMed ID: 25248882 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2015
| ||||||||||||||
| Property / Publication Date: 2015 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Published In Name String | |||||||||||||||
| + | Leuk. Lymphoma | ||||||||||||||
| Property / Published In Name String: Leuk. Lymphoma / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Volume | |||||||||||||||
| + | 56 | ||||||||||||||
| Property / Volume: 56 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / title | |||||||||||||||
| + | A phase 1 study of the safety pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed refractory or high-risk acute myeloid leukemia (English) | ||||||||||||||
| Property / title: A phase 1 study of the safety pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed refractory or high-risk acute myeloid leukemia (English) / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Page(s) | |||||||||||||||
| + | 1406-1415 | ||||||||||||||
| Property / Page(s): 1406-1415 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| links / sliswiki / name | links / sliswiki / name | ||||||||||||||
| + | |||||||||||||||
Latest revision as of 15:45, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
He SZ, et al. Leuk. Lymphoma (2015) cited as Ref 556 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
He SZ
0 references
2015
0 references
Leuk. Lymphoma
0 references
56
0 references
A phase 1 study of the safety pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed refractory or high-risk acute myeloid leukemia (English)
0 references
1406-1415
0 references
